Chemomab Therapeutics
CMMB
9 hedge funds and large institutions have $2.28M invested in Chemomab Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 9 → 9 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.05% → 0.04% (-0.01%)
56% less capital invested
Capital invested by funds: $5.22M → $2.28M (-$2.94M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$46.3K |
| 2 |
VF
Virtu Financial
New York
|
+$39.7K |
| 3 |
Morgan Stanley
New York
|
+$33.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$972 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$972 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$448K |
| 2 |
RI
RTW Investments
New York
|
-$233K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$214K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
1
Meitav Investment House
Bene-Beraq,
Israel
| $972K | +$46.3K | +238 | +4% |
|
|
PCM
2
Palisade Capital Management
Fort Lee,
New Jersey
| $850K | – | – | – |
|
|
KCM
3
Kennedy Capital Management
St Louis,
Missouri
| $295K | -$214K | -1,101 | -35% |
|
|
PF
4
Phoenix Financial
Givatayim,
Israel
| $57K | +$79.3K | +408 | New |
|
|
5
Fidelity Investments
Boston,
Massachusetts
| $50K | -$23.1K | -119 | -26% |
|
|
VF
6
Virtu Financial
New York
| $30K | +$39.7K | +204 | New |
|
|
7
Morgan Stanley
New York
| $25K | +$33.1K | +170 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1K | +$972 | +5 | +500% |
|
|
AIC
9
AWM Investment Company
New York
| – | -$448K | -1,563 | Closed |
|
|
RI
10
RTW Investments
New York
| – | -$233K | -811 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$6K | -22 | Closed |
|
|
12
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$972 | +5 | New |
|
CMMB Hedge Fund Activity: Q3 2019 in Review
9 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2019, worth a combined $2.28M — down 56% from $5.22M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CMMB positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Meitav Investment House, adding an estimated $46.3K. The largest seller was AWM Investment Company, exiting entirely with an estimated $448K sold.
- 9 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $2.28M of Chemomab Therapeutics stock for Q3 2019, down 56% quarter-over-quarter.
- 4 funds opened new Chemomab Therapeutics positions in Q3 2019 and 3 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q3 2019 was Meitav Investment House, an estimated $46.3K added.
- The largest Chemomab Therapeutics seller in Q3 2019 was AWM Investment Company, an estimated $448K sold.
Based on aggregated 13F filings for Q3 2019.